It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
CAMBRIDGE, England & BAD HOMBURG, Germany--(BUSINESS WIRE)--Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that ...
TOKYO--(BUSINESS WIRE)--PHC Corporation Biomedical Division (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura, hereinafter referred to as "Biomedical Division") will showcase a prototype ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...
Emily Whitehead made the history books in 2012 when she become the first pediatric patient with B-cell acute lymphoblastic leukemia to be given a chimeric antigen receptor (CAR) T-cell therapy. After ...
Cellares unveiled Cell Q Thursday, the first automated quality control (QC) workcell for cell therapy manufacturing. According to the company, Cell Q complements its Cell Shuttle Platform by ...
LONDON, March 9, 2026 /PRNewswire/ -- The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results